Welcome to our dedicated page for Onconetix news (Ticker: BWV), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. (Nasdaq: ONCO), formerly Blue Water Biotech (BWV), delivers cutting-edge oncology therapeutics and diagnostics through products like ENTADFI® for prostate health and Proclarix® for cancer risk assessment. This page provides investors and healthcare professionals with essential updates on FDA approvals, clinical advancements, and strategic initiatives following the company’s acquisition of Proteomedix AG.
Access real-time insights into Onconetix’s commercial-stage developments, including product launches, partnership announcements, and financial disclosures. Our curated news collection ensures you stay informed about innovations in prostate cancer diagnostics and BPH treatment without speculative commentary.
Key updates include regulatory milestones for Proclarix®’s U.S. launch, ENTADFI®’s market performance, and executive leadership strategies under CEO Dr. Neil J. Campbell. Bookmark this page to monitor Onconetix’s progress in addressing unmet needs in oncology care while maintaining awareness of critical investment developments.
Blue Water Vaccines (BWV) has announced a collaboration with the Center for R&D in Immunobiologics in Brazil to develop its universal influenza vaccine candidate, BWV-101. This partnership is supported by a grant from the State of Sao Paulo Research Foundation, aiming for national autonomy in vaccine production. The project involves major institutions, including the University of Oxford. BWV-101 aims to provide comprehensive protection against various influenza strains. The vaccine is being developed using an E. coli expression platform for cost-effective production.
Blue Water Vaccines Inc. (BWV) has successfully closed its initial public offering, selling 2,222,222 shares at $9.00 each, generating approximately $20 million in gross proceeds. As of March 31, 2022, the company reported cash reserves of $18.6 million, significantly up from $1.9 million at the end of 2021. Recent developments include advancements in its vaccine pipeline, particularly with BWV-101, a universal influenza candidate showing promising new data. R&D expenses rose to $0.46 million, with a net loss of $2.1 million reported for Q1 2022, compared to $0.3 million in the same quarter last year.
Blue Water Vaccines (BWV) announced that Erin Henderson, Chief Business Officer, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 9:00 AM EDT. The presentation will be available via on-demand webcast. BWV focuses on developing transformative vaccines, including a universal flu vaccine and candidates for norovirus and pneumococcus. The company utilizes proprietary technology from renowned institutions, aiming to tackle global health challenges. For more details, visit bluewatervaccines.com.
Blue Water Vaccines (BWV) has expanded its license agreement with St. Jude Children's Research Hospital to develop a novel bacterial vaccine platform targeting acute otitis media (AOM) caused by Streptococcus pneumoniae. This collaboration aims to utilize newly identified antigens and improve protection against multiple infectious diseases. Preliminary research indicates potential effectiveness against both S. pneumoniae and non-typeable Haemophilus influenzae. The company anticipates addressing a significant public health issue, with AOM affecting over 5 million U.S. children annually.
Blue Water Vaccines (BWV) recently presented at the World Vaccine Congress 2022, showcasing their findings on H3N2 and influenza B epitopes, which are crucial for developing their universal influenza vaccine, BWV-101. These findings, stemming from collaborative research with The University of Oxford, build on previous data related to H1 influenza. BWV emphasizes the need for improved vaccines, given the significant burden of influenza, which results in over 1 billion infections annually. The company has filed provisional patents for the new antigens, reinforcing their commitment to vaccine innovation.
Blue Water Vaccines Inc. announced the closing of a private placement of 1,180,812 shares priced at $6.775 per share, generating approximately $8.0 million in gross proceeds. The funds will be allocated for the research and development of vaccine candidates BWV-101, BWV-102, and BWV-103, as well as general corporate purposes. The investment options provided to investors have an exercise price of $6.65 and are exercisable for four years. The securities issued are not publicly traded and will be registered within 20 days following April 13, 2022.
Oragenics, Inc. (NYSE American: OGEN) announced its participation in the World Vaccine Congress Washington from April 18-22, showcasing its lead product, NT-CoV2-1, an intranasal COVID-19 vaccine candidate. The vaccine aims for patient-friendly administration and robust immune response. NT-CoV2-1 has shown promising results in animal studies, with a Phase 1 trial expected to begin this year. Kimberly Murphy, a board member and former GSK executive, will represent the company. Oragenics focuses on combating infectious diseases, leveraging research from NIH and NRC.
Blue Water Vaccines has entered into agreements for a private placement, securing approximately $8.0 million through the sale of 1,180,812 shares of common stock at $6.775 each. Additionally, unregistered preferred investment options for the same number of shares will be issued at an exercise price of $6.65, exercisable for four years. Proceeds will fund the research and development of vaccine candidates BWV-101, BWV-102, and BWV-103. The closing is anticipated around April 18, 2022.
Blue Water Vaccines (BWV) announced a presentation on its universal influenza vaccine candidate at the World Vaccine Congress 2022. Scheduled for April 20, 2022, Brian Price, Ph.D., will represent the company, discussing the vaccine's innovative development utilizing licensed epitopes from The University of Oxford. CEO Joseph Hernandez emphasized BWV's commitment to tackling global health challenges with breakthroughs in vaccine technology. The company is also exploring vaccines for norovirus, malaria, and pneumococcus.
Blue Water Vaccines (BWV) has exclusive licensing rights to Cincinnati Children’s Hospital Medical Center’s (CCHMC) novel virus-like particle (VLP) vaccine platform. This supports BWV's development of a universal influenza vaccine and vaccines for norovirus and rotavirus to combat gastroenteritis. A recent research paper published by CCHMC enhances the potential of the VLP platform, focusing on HA1 antigens for flu vaccines. The partnership aims to address significant health challenges globally, as current vaccines are limited and many infectious diseases remain without effective vaccines.
